Tamiflu is more effective at relieving flu symptoms than a combination of tamiflu and relenza
2010-11-03
(Press-News.org) In adults with seasonal influenza A virus infection, the combination of the drugs oseltamivir (tamiflu) and zanamivir (relenza) is less effective than oseltamivir monotherapy and not significantly more effective than zanamivir monotherapy. This key finding comes from a randomized, placebo-controlled trial— in adults presenting with influenza symptoms at general practices throughout France during the seasonal influenza epidemic in 2008-2009— carried out by Catherine Leport from the University of Paris, France, and colleagues, and reported in this week's PLoS Medicine.
In the past few years oseltamivir and zanamivir have been key drugs for limiting the impact of seasonal influenza both in individuals (by reducing morbidity and mortality) and collectively (by slowing the virus' spread to buy time for vaccine production). In order to inform future influenza pandemic planning, the authors compared the effectiveness of monotherapy with either oseltamivir or zanamivir with the effectiveness of an oseltamivir-zanamivir combination.
Adults who visited their GP with symptoms of an influenza-like illness for less than 36 hours and who had a positive influenza A rapid test were randomized to one of three arms: 1) oral oseltamivir 75 mg twice daily plus zanamivir 10 mg by inhalation twice daily 2) oral oseltamivir 75 mg twice daily plus inhaled placebo or 3) zanamivir 10 mg by inhalation twice daily plus oral placebo. 541 patients were enrolled in the study (192 in group 1; 176 in group 2; and 173 in group 3) of whom 447 were infected with influenza A. Overall the oseltamivir-zanamivir combination was both virologically and clinically less effective than oseltamivir monotherapy. In addition, the clinical effects of the oseltamivir-zanamivir combination on time to resolution of symptoms were not significantly different from that of zanamivir monotherapy.
The authors conclude that their findings call for caution in the use of the oseltamivir-zanamivir combination in treatment of adult outpatients with influenza. Furthermore, as the virological effects of oseltamivir monotherapy over zanamivir monotherapy were superior in this trial, the authors say:
"Oseltamivir should be the recommended primary anti-influenza treatment during influenza seasons with predominant H3N2 viruses naturally susceptible to oseltamivir."
INFORMATION:
Funding: This work was supported by a research grant from the French Ministry of Health. The sponsor was: Departement a la Recherche Clinique et au Developpement, Assistance Publique a` Hopitaux de Paris (Programme hospitalier de recherche clinique, AOM 06060 and AOM 08209). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: XD has had a conference invitation from GSK and lecture fees from Roche and Gilead. AM has membership in the ministry of health advisory board on influenza; involvement in some epidemiological studies partially or fully granted by Roche and GSK, and travel grants from Roche for participation in scientific meetings. SVDW has had a conference invitation from GSK; research grant from GSK on unrelated subject; joint patent from institution with GSK on unrelated subject; travel grants for meetings from GSK; contribution to clinical trial financed by Roche; member of the advisory committee on influenza of the French ministry of health; is a member of ESWI; is a member of the scientific committee of the GEIG; and is vice-president of the GROG network. FM received fees from Roche, preclinical pharmacokinetic department, for a course on MONOLIX in December 2008. BL has had paid consultancy and board membership (Roche, GSK, Novartis, BioCryst, MedImmune), has had research grants from Roche and Sanofi-Pasteur, and had received travel grants and honoraria for speaking or participation at meetings (Roche, Sanofi-Pasteur).
Citation: Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, et al. (2010) Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial. PLoS Med 7(11): e1000362. doi:10.1371/journal.pmed.1000362
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000362
PRESS-ONLY PREVIEW OF THE ARTICLE: www.plos.org/press/plme-07-09-leport.pdf
CONTACT:
Catherine Leport
Université Paris Diderot Paris 7
Maladies infectieuses
16 rue Henri Huchard
PARIS, Ile de France 75018
France
33 1 57 27 78 68
33 1 57 27 76 91 (fax)
catherine.leport@univ-paris-diderot.fr
END
ELSE PRESS RELEASES FROM THIS DATE:
2010-11-03
In this week's PLoS Medicine Magazine, Trisha Greenhalgh and Jill Russell from the Queen Mary University of London discuss the relative merits of "scientific" and "social practice" approaches to evaluation and argue that eHealth evaluation is in need of a paradigm shift. They critique the previous PLoS Medicine series on evaluating eHealth, published in late 2009.
INFORMATION:Funding: The ideas in this paper were developed during an independent evaluation of the UK Summary Care Record programme, funded by a research grant from the UK National Institute of Health Research ...
2010-11-03
David Henry discusses a recent research article in PLoS Medicine that suggests that relationships between doctors and drug companies are still too close. The research, by Geoffrey Spurling and colleagues, examined the relationship between exposure to promotional material from pharmaceutical companies and the quality, quantity, and cost of prescribing. David Henry's offers his Perspective in this week's PLoS Medicine Magazine.
INFORMATION:
Funding: The author received no specific funding for this article
Competing Interests: The author has declared that no competing ...
2010-11-03
BOSTON—The system for hospice admissions for patients with advanced dementia, which is a terminal illness, should be guided by patient and family preference for comfort, not estimated life expectancy, says a new study published in the Nov. 3 Journal of the American Medical Association by the Institute for Aging Research at Hebrew SeniorLife, an affiliate of Harvard Medical School.
Currently, patients requesting hospice services must be certified by their physician to have six months or less to live, and must sign a statement choosing comfort care services in lieu of curative ...
2010-11-03
In a study examining the factors that play a role in an older adult's transition to disability, intervening illnesses and injuries that led to hospitalization or activity restriction were associated with worsening functional ability, especially among those who were physically frail, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Thomas M. Gill, M.D., of the Yale University School of Medicine, New Haven, Conn., presented the findings of the study at a JAMA media briefing at the National Press Club.
Among older persons, disability in essential ...
2010-11-03
Use of a fall prevention tool kit, which included a fall risk assessment, patient-specific prevention plan, an educational handout and a poster for over the patient's hospital bed reduced the number of older patients with falls in hospitals, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Patricia C. Dykes, R.N., D.N.Sc., of Partners HealthCare System, Brigham and Women's Hospital and Harvard Medical School, Boston, presented the findings of the study at a JAMA media briefing at the National Press Club.
"Falls are a public health problem ...
2010-11-03
In a review of comprehensive primary care programs for older adults with multiple chronic conditions, authors identified three models that appear to have the greatest potential for improving quality of care and life for these patients, while reducing or not increasing the costs of their health care, according to an article in the November 3 issue of JAMA, a theme issue on aging.
Chad Boult, M.D., M.P.H., M.B.A., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, presented the findings of the study at a JAMA media briefing at the National Press Club.
"Older ...
2010-11-03
Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Joseph F. Quinn, M.D., of Oregon Health and Science University and the Portland VA Medical Center, Portland, Ore., presented the findings of the study at a JAMA media briefing at the National ...
2010-11-03
VIDEO:
Researchers show that obesity-induced heart disease can be prevented by reducing the activity of TOR, a nutrient-sensing protein that regulates molecular circuits involved in growth, metabolism and lifespan.
Click here for more information.
LA JOLLA, Calif., November 2, 2010 – It's no secret that obesity is hard on the heart. More than 30 percent of Americans are obese, and many of them are also at increased risk for cancer, diabetes and heart disease. However, there ...
2010-11-03
Survival for colorectal cancer patients with MUTYH-associated polyposis was statistically significantly better than for patients with colorectal cancer from the general population, according to a recent study published online November 2 in The Journal of the National Cancer Institute.
People who inherit a mutation in the MUTYH gene have nearly a 100% risk for developing colon cancer at some point in their lifetimes. But it is unknown whether specific histological and molecular genetic features of cancer associated with this genotype influence tumor behavior and survival. ...
2010-11-03
A team led by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, has captured the most comprehensive snapshot to date of DNA regions that regulate genes in human pancreatic islet cells, a subset of which produces insulin.
The study highlights the importance of genome regulatory sequences in human health and disease, particularly type 2 diabetes, which affects more than 20 million people in the United States and 200 million people worldwide. The findings appear Nov. 3 in Cell Metabolism.
"This study applies ...
LAST 30 PRESS RELEASES:
[Press-News.org] Tamiflu is more effective at relieving flu symptoms than a combination of tamiflu and relenza
